Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2018.0275

PERSPECTIVE

Trastuzumab – emtansine for HER2-positive breast cancer patients and development of new therapies.

Prof. George Zografos, MD, PhD.

Affiliation:Head of the Breast Unit, Head of 1st Department of Propaedeutic Surgery, University of Athens, Greece.

Tel: +306932524836

E-mail: gzografo@med.uoa.gr

Abstract
The trastuzumab – emtansine conjugate has been approved 5-years ago for the treatment of metastatic HER2 – positive breast cancer following treatment with chemotherapy plus trastuzumab. This significant overall survival prolongation has led to several underway phase III randomized clinical trials evaluating the efficacy of trastuzumab – emtansine as first line therapy in the metastatic over adjuvant setting.
This perspective article discusses beyond the targets of this conjugate as well as other novel therapies for effective breast cancer treatment.

(Citation: Gastric & Breast Cancer 2018; 13(1): 50-70)

Back

 

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 31 March 2018